Menu Search
Equities

Hemostemix Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2VF0:FRA

Hemostemix Inc

Actions
  • Price (EUR)0.04
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-49.69%
  • Beta0.5828
Data delayed at least 15 minutes, as of Feb 13 2026 14:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-3.40m
  • Incorporated2014
  • Employees--
  • Location
    Hemostemix Inc707 7th Ave. SW, Suite 1150CALGARY T2P 3H6CanadaCAN
  • Phone+1 (905) 580-4170
  • Fax+1 (403) 818-7672
  • Websitehttps://hemostemix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.